Clinical Trial ProgressSernova's Phase 1/2 study results are indicative of the trial being on track to succeed and help de-risk any upcoming data readouts and subsequent studies.

Product InnovationThe addition of tegoprubart to Sernova’s Cell Pouch platform is expected to enable patients to achieve insulin independence with significantly less toxicity.

Research CollaborationA new research agreement with Eledon Pharmaceuticals aims to enhance cell pouch safety in Sernova's clinical development, potentially improving the therapy for patients with type 1 diabetes.

Bears Say

Sernova News

Sernova Biotherapeutics Strengthens Financial Position with Debt-to-Equity Conversion

Sernova ( ($TSE:SVA) ) has provided an announcement. Sernova Biotherapeutics announced a significant financial restructuring by converting approximately...

23d ago

Sernova Biotherapeutics Appoints John L. Brooks III as Board Chair to Advance Diabetes Cure

The latest announcement is out from Sernova ( ($TSE:SVA) ). Sernova Biotherapeutics has appointed John L. Brooks III...

1M ago

Sernova Biotherapeutics to Present at Global Investment Conference

Sernova ( ($TSE:SVA) ) has issued an update. Sernova Biotherapeutics announced its participation in the H.C. Wainwright 27th...

2M ago

Sernova and Eledon Collaborate on Potential Type 1 Diabetes Cure

The latest update is out from Sernova ( ($TSE:SVA) ). Sernova Biotherapeutics has announced a collaboration with Eledon...

4M ago

Promising Advancements and Strategic Partnerships Bolster Sernova’s Buy Rating for T1D Treatment

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Sernova today and set a price target of...

4M ago

Sernova’s Promising T1D Treatment Strategy Gains Confidence with External Validation and Unique Cell Pouch System

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Sernova (SVA – Research Report) today and set...

4M ago

Sernova Biotherapeutics Appoints Interim Chair Amid Strategic Advancements

Sernova ( ($TSE:SVA) ) has shared an announcement. Sernova Biotherapeutics has appointed its CEO, Jonathan Rigby, as the...

5M ago

Sernova Biotherapeutics Forms Clinical Advisory Board to Advance Diabetes Treatment

Sernova ( ($TSE:SVA) ) just unveiled an announcement. Sernova Biotherapeutics has announced the formation of a Clinical Advisory...

5M ago

Sernova’s Cell Pouch Shows Promising Results in Diabetes Trial

Sernova ( ($TSE:SVA) ) has provided an update. Sernova Biotherapeutics announced positive interim data from its ongoing Phase...

5M ago

Promising Interim Data from Sernova’s Cell Pouch Trial Boosts Stock Potential

In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Sernova (SVA –...

5M ago

SVA FAQ

What was Sernova Corp’s price range in the past 12 months?

Sernova Corp lowest stock price was C$0.14 and its highest was C$0.27 in the past 12 months.

What is Sernova Corp’s market cap?

Sernova Corp’s market cap is C$54.23M.

When is Sernova Corp’s upcoming earnings report date?

Sernova Corp’s upcoming earnings report date is Mar 19, 2026 which is in 145 days.

How were Sernova Corp’s earnings last quarter?

Sernova Corp released its earnings results on Sep 15, 2025. The company reported -C$0.01 earnings per share for the quarter, beating the consensus estimate of -C$0.02 by C$0.01.

Is Sernova Corp overvalued?

According to Wall Street analysts Sernova Corp’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Sernova Corp pay dividends?

Sernova Corp does not currently pay dividends.

What is Sernova Corp’s EPS estimate?

Sernova Corp’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Sernova Corp have?

Sernova Corp has 328,690,640 shares outstanding.

What happened to Sernova Corp’s price movement after its last earnings report?

Sernova Corp reported an EPS of -C$0.01 in its last earnings report, beating expectations of -C$0.02. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Sernova Corp?

Currently, no hedge funds are holding shares in TSE:SVA

Company Description

Sernova Corp

Sernova Corp. (SVA) is a clinical-stage regenerative medicine company focused on developing and commercializing therapeutic cell technologies to treat chronic diseases such as diabetes, hemophilia, and thyroid disease. The company is headquartered in Canada and operates within the biotechnology sector. Its core product is the Cell Pouch System, an implantable medical device designed to create a natural environment for the survival and function of therapeutic cells, which can produce necessary proteins or hormones that are deficient in patients.